Duprey Lauren Rusckowski 4
4 · TAKEDA PHARMACEUTICAL CO LTD · Filed Apr 28, 2026
Research Summary
AI-generated summary of this filing
Takeda (TAK) Chief Transformation Officer Duprey Receives 59,990 RSUs
What Happened
Lauren Duprey Rusckowski, Chief Transformation Officer at Takeda Pharmaceutical (TAK), received an award of 59,990 restricted stock units (RSUs) on April 27, 2026. The filing reports the RSUs at $0.00 (typical for grant reporting); these RSUs are performance-based and the number awarded was determined by the Compensation Committee based on specified performance metrics.
Key Details
- Transaction date and type: 2026-04-27 — Grant/Award (code A). Report filed 2026-04-28 (timely).
- Reported price/value: $0.00 per share; total reported value $0 (grant reported, not cash proceeds).
- Holdings noted in footnotes: the filing references 146,762 RSUs currently included in holdings; those RSUs vest on July 1, 2026 (100,658), July 1, 2027 (30,488) and July 1, 2028 (15,616).
- Footnote on award: the original award was granted July 1, 2023 and vests as American Depositary Shares based on achievement of core revenue, core operating profit and R&D milestones; on 4/27/2026 the committee determined the performance payout (the 59,990 RSUs reported).
- Filing timeliness: reported the next day — not marked late.
Context
This was an equity award (not an open-market buy or sale). Performance-based RSU grants are contingent on achieving targets and vest over time or upon committee determination; they do not by themselves indicate an insider buying or selling stock. The RSUs represent a right to receive American Depositary Shares if and when vesting conditions are met.
Insider Transaction Report
- Award
American Depositary Shares
[F1][F2]2026-04-27+59,990→ 228,503 total
Footnotes (2)
- [F1]On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above.
- [F2]Includes 146,762 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (100,658 shares), July 1, 2027 (30,488 shares) and July 1, 2028 (15,616 shares).